Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Change in Acquisitions & Divestments (2024 - 2025)

SAB Biotherapeutics' Change in Acquisitions & Divestments history spans 2 years, with the latest figure at $11.3 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 5.38% year-over-year to $11.3 million; the TTM value through Dec 2025 reached $21.3 million, changed N/A, while the annual FY2025 figure was $21.3 million, 17.66% down from the prior year.
  • Change in Acquisitions & Divestments reached $11.3 million in Q4 2025 per SABSW's latest filing, up from $5.2 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $11.3 million in Q4 2025 to a low of $3.8 million in Q3 2024.